Our understanding of cerebrovascular disease in women is hampered by a paucity of studies that include adequate numbers of female patients. Most studies are heavily biased toward men. Although women have fewer strokes than men and have a better long-term prognosis after strokes or TIAs, cerebrovascular disease still affects large numbers of women. Presently, there is little convincing evidence that standard medical therapy with aspirin for prevention of strokes in women is of benefit. Perhaps, inclusion of insufficient numbers of women in the aspirin trials for symptomatic carotid stenoses explains the apparent lack of therapeutic efficacy. Although ticlopidine does not appear particularly promising for prevention of stroke, other novel antiplatelet and antithrombotic agents are being developed and need to be tested in women. Carotid endarterectomy prevents strokes in women and men, but women enjoy a lesser benefit; this appears to be true both for symptomatic and asymptomatic carotid stenoses. Whereas restenosis is more common in women than men, most lesions remain asymptomatic. Surgery will probably remain the mainstay of treatment for cerebrovascular disease in women and men, but in this era of "gender correctness," the striking absence of reliable data exclusively applicable to women confirms the need for additional studies.